2m 2m 2m 2m 2m 2m 2m
BIOAGE LABS (BIOA)
NASDAQ
$16.06-$0.48 (-2.90%)
Price as of Jun 03, 2026 6:48 PM EDT- $768.6MMarket Cap
- 314.54%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
BIOAGE LABS (BIOA)
$16.06-$0.48 (-2.90%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 9.0M N/A | N/A N/A | |
Cost of Revenue | 49.4M +33.17% | 37.1M N/A | |
Gross Profit | -40.5M +8.95% | -37.1M N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -74.0M +25.29% | -59.0M N/A | |
Depreciation and Amortization Expense | 200,000 0.00% | 200,000 N/A | |
Total Operating Expenses | 101.8M +30.16% | 78.2M N/A | |
Operating Profit | -92.8M +18.65% | -78.2M N/A | |
Interest Income | 13.1M +35.90% | 9.6M N/A | |
Interest Expense | -700,000 -58.82% | -1.7M N/A | |
Interest Income and Expense and Net | 12.4M +56.21% | 7.9M N/A | |
Total Nonoperating Income and Expense | 12.2M +71.84% | 7.1M N/A | |
Income before Taxes | -92.8M +18.65% | -78.2M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -80.6M +13.35% | -71.1M N/A | |
Net Income from Continuing Operations Applicable to Common | -80.6M +13.35% | -71.1M N/A | |
Basic EPS and Net Income | -2.24 -66.21% | -6.63 N/A | |
Diluted EPS and Net Income | -2.24 -66.21% | -6.63 N/A | |
Basic Weighted Average Shares | 35.9M +234.99% | 10.7M N/A | |
Diluted Weighted Average Shares | 35.9M +234.99% | 10.7M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 188.9M -46.69% | 354.3M N/A | |
Short-Term Investments | 92.2M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 281.1M -20.67% | 354.3M N/A | |
Total Current Assets | 286.8M -19.69% | 357.1M N/A | |
Accumulated Depreciation | 482,000 +29.92% | 371,000 N/A | |
Property and Plant and Equipment and Net | 963,000 +62.94% | 591,000 N/A | |
Total Long-Term Assets | 216,000 -10.00% | 240,000 N/A | |
Total Assets | 294.9M -17.68% | 358.2M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 2.6M -55.87% | 6.0M N/A | |
Total Current Liabilities | 20.1M -27.50% | 27.8M N/A | |
Total Long-Term Debt | 0 -100.00% | 2.5M N/A | |
Total Long-Term Liabilities | 2.7M -63.18% | 7.3M N/A | |
Total Liabilities | 22.8M -34.95% | 35.1M N/A | |
Retained Earnings | -333.4M +31.88% | -252.8M N/A | |
Total Stockholders Equity | 272.1M -15.81% | 323.1M N/A | |
Total Shares Outstanding | 37.4M +4.29% | 35.9M N/A | |
Cash Flow | |||
Cash from Operating Activities | -81.6M +58.43% | -51.5M N/A | |
Capital Expenditures | 719,000 +96.45% | 366,000 N/A | |
Cash from Investing Activities | -95.2M +25,915.30% | -366,000 N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 11.5M -96.99% | 381.2M N/A | |
Financials Ratio | |||
Gross Margin | -449.74% N/A | N/A N/A | |
Operating Margin | -1,031.46% N/A | N/A N/A | |
Return on Assets | -24.68% N/A | N/A N/A | |
Return on Equity | -27.09% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 14.24 N/A | N/A N/A | |
Cash Ratio | 9.38 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.010 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.009 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow